2019 American Transplant Congress
A Comparison of the Safety and Efficacy of Apixaban Use in Renal Transplant vs. Non-Renal Transplant Recipients
University of Alabama at Birmingham Hospital, Birmingham, AL
*Purpose: Background: Utilization of direct-acting oral anticoagulants has become a preferred method for chronic anticoagulation in patients with atrial fibrillation (AF) or venous thromboembolism (VTE).…2019 American Transplant Congress
Novel Oral Anticoagulants in Kidney Transplantation: Results from a Pilote Study
Adult Transplantation, Necker Hospital, Paris, France
*Purpose: Oral anticoagulation therapy is frequently prescribed to kidney transplant recipients, for prevention and treatment of thrombotic events. Over the past ten years, novel oral…2019 American Transplant Congress
When to Hold: Apixaban in Renal Transplant Recipients
1Yale New Haven Hospital, New Haven, CT, 2Yale School of Medicine, New Haven, CT
*Purpose: Renal transplant recipients (RTRs) may develop deep venous thrombosis (DVT), pulmonary embolism (PE), or atrial fibrillation requiring treatment with oral anticoagulation. There is limited…2019 American Transplant Congress
Postoperative Atrial Fibrillation in Kidney Transplant Recipients: A Retrospective Study Evaluating Risk of Anticoagulation
*Purpose: Patients with atrial fibrillation (AF) have a higher risk of mortality and adverse cardiovascular events. Pre-operative AF has around 5-9% prevalence and roughly 5%…2019 American Transplant Congress
Effect of Enoxaparin Prophylaxis on Early VTE Post Lung Transplant
*Purpose: Thromboembolic complications are common post-transplant leading to significant morbidity. We instituted early enoxaparin prophylaxis (ppx) in lung transplant recipients (LTR) due to an observed…2019 American Transplant Congress
Safety and Efficacy of Anti Xa Inhibitors Post-Transplant with Concomitant Calcineurin Inhibitors
*Purpose: Despite demonstrated benefits of Anti-Xa Inhibitors (ATIs) in the general population, ATIs have not gained uniform acceptance in SOT due to lack of supportive…2019 American Transplant Congress
Apixaban Therapy Is Safe And Effective In Most Organ Transplant Populations
University of Virginia Health System, Charlottesville, VA
*Purpose: The bleed rates from the apixaban pivotal trial were 12.1% for non-major and 3.8% major bleeds. However outcomes in transplant recipients are less defined,…2018 American Transplant Congress
The Impact of Anticoagulation Therapy Modifications during the Index Hospitalization on Clinical Outcomes in Kidney Transplant Recipients
Medical University of South Carolina, Charleston, SC.
Background: The aim of this study was to determine whether changing anticoagulation medications during the index admission for kidney transplant (KT) is significantly associated with…2018 American Transplant Congress
Direct Oral Anticoagulation Use in Kidney Transplant Recipients
1MedStar Georgetown University Hospital, Washington DC; 2Michigan Medicine, Ann Arbor, MI.
Objective: There is a lack of high-level evidence identifying meaningful outcomes with direct oral anticoagulants (DOACs) in kidney transplant recipients. The primary objective of this…2018 American Transplant Congress
Recent Exposure to Four-Factor Prothrombin Complex Concentrate (4F-PCC) is Associated with Intracardiac Thrombus during Liver Transplantation
BackgroundPatients with ESLD often have imbalance in hemostasis & monitoring traditional coagulation lab markers are generally not helpful. Intracardiac thrombus (ICT) during liver transplant (LT)…
American Transplant Congress abstracts